1. Signaling Pathways
  2. Anti-infection
  3. HIV

HIV

Human immunodeficiency virus

HIV (Human immunodeficiency virus) is a lentivirus (a subgroup of retrovirus) that causes the acquired immunodeficiency syndrome (AIDS), a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. Infection with HIV occurs by the transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk. Within these bodily fluids, HIV is present as both free virus particles and virus within infected immune cells. HIV infects vital cells in the human immune system such as helper T cells (specifically CD4+ T cells), macrophages, and dendritic cells. HIV infection leads to low levels of CD4+ T cells through a number of mechanisms, including apoptosis of uninfected bystander cells, direct viral killing of infected cells, and killing of infected CD4+ T cells by CD8 cytotoxic lymphocytes that recognize infected cells. When CD4+ T cell numbers decline below a critical level, cell-mediated immunity is lost, and the body becomes progressively more susceptible to opportunistic infections.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-179348
    DPP9-IN-2
    Inhibitor
    DPP9-IN-2 is a selective, potent and orally active inhibitor of Dipeptidyl Peptidase 9 (DPP9 ) with an IC50 of 12.9 nM. DPP9-IN-2 shows a SI of 59 over DPP8, and shows no significant inhibitory activity against related peptidases including DPP2, DPP4, FAP, and PREP. DPP9-IN-2 can induce cancer cells pyroptosis and has weak synergistic anti-HIV-1 activity when combined with non-nucleoside reverse transcriptase inhibitor. DPP9-IN-2 can be used for the researches of cance rand infection.
    DPP9-IN-2
  • HY-170483
    Antitumor agent-191
    Inhibitor
    Antitumor agent-191 (Compound 7) exhibits antiviral activity against HSV-1 and HIV with EC50 of 0.03 μM and 0.81 μM. Antitumor agent-191 exhibits potential antitumor efficacy, that inhibits cancer cell HepG2, WI-38, Vero and MCF-7, with IC50s of 19.6, 39.3, 18.3 and 28 μM, respectively.
    Antitumor agent-191
  • HY-154794
    Antiviral agent 29
    Inhibitor
    Antiviral agent 29 (one of the Example I), a 2-mercapto-N-(5-amino-1,2,4-triazol-3-yl) benzenesulfonamide derivative, is an antiviral agent exhibiting anti-HIV, antitumor and antiarrhythmic activities.
    Antiviral agent 29
  • HY-121611
    HI-236
    Inhibitor
    HI-236 is a potent non-nucleoside inhibitor of HIV-1 reverse transcriptase.? HI-236 inhibits HIV activity (wild type HTLVIIB IC50p24 < 0.001 μM).
    HI-236
  • HY-N11430
    F1839-I
    Inhibitor
    F1839-I is a compound that can be isolated from Stachybotrys. F1839-I has weak cytotoxicity and anti-HIV activity with an IC50 value of 15.6 μM.
    F1839-I
  • HY-182552
    Soulattrolide
    Inhibitor
    Soulattrolide is a non-nucleoside HIV-1 reverse transcriptase (RT) inhibitor with IC50 values of 0.34 µM for HIV-1 RT, 69.5 µM for E. coli RNase H, and >495 µM for human DNA polymerase β, and can be found in Calophyllum teysmannii latex. Soulattrolide can be used for the research of HIV-1 infection, pain, inflammation, and Mycobacterium tuberculosis infection.
    Soulattrolide
  • HY-13004R
    Maraviroc (Standard)
    Inhibitor
    Maraviroc (Standard) is the analytical standard of Maraviroc. This product is intended for research and analytical applications. Maraviroc (UK-427857) is a selective CCR5 antagonist with activity against human HIV.
    Maraviroc (Standard)
  • HY-129289
    NSC 13987
    Inhibitor
    NSC 13987 is a Nef site I inhibitor. NSC 13987 binds to Nef site I and disrupts the Nef-calnexin interaction. NSC 13987 restores cholesterol efflux inhibited by Nef. NSC 13987 is applicable to the research of HIV-associated atherosclerosis.
    NSC 13987
  • HY-P10437
    VIRIP
    Inhibitor
    VIRIP (human α1-AT(353-372)) is a HIV-1 inhibitor. VIRIP blocks the entry of HIV-1 by interacting with gp41 fusion peptide. VIRIP can be used for virus research.
    VIRIP
  • HY-P11152
    HIV-1 tat Protein (1-9)
    Inhibitor
    HIV-1 tat Protein (1-9) occurs extracellularly and has a role in the immunosuppression of non-HIV-1-infected T cells in acquired AIDS. HIV-1 tat Protein (1-9) is an inhibitor of DP IV. HIV-1 tat Protein (1-9) can be synthesized by phase peptide synthesis with Fmoc (N-(9-fluorenyl)methoxycarbonyl) technique using the peptide synthesizer 431A. HIV-1 tat Protein (1-9) can be studied in research on HIV-1.
    HIV-1 tat Protein (1-9)
  • HY-113818
    Kadsuracoccinic acid A
    Inhibitor
    Kadsuracoccinic acid A is a tetracyclic natural compound that can be isolated from the stems of Kadsura coccinea. Kadsuracoccinic acid A has vitro anti-HIV-1 activitiy with an EC50 value of 68.7 μM.
    Kadsuracoccinic acid A
  • HY-107401
    Ancriviroc
    Inhibitor
    Ancriviroc (SCH-351125) is an orally active CCR5 antagonist with an IC50 value of 13 nM against hCCR5. Ancriviroc specifically binds to hCCR5, blocks ligand-induced signal transduction, calcium influx, GTPγS binding, chemotaxis, ligand binding, and HIV-1 entry, induces conformational changes in CCR5, and inhibits infection and replication of R5-tropic HIV-1.
    Ancriviroc
  • HY-147808
    CXCR4 antagonist 7
    Inhibitor
    CXCR4 antagonist 7 (Compound PARA-B) is a CXCR4 antagonist with the IC50 of 9.3 nM. CXCR4 antagonist 7 can be used for the research of HIV infection, inflammatory diseases, cancer, and WHIM syndrome.
    CXCR4 antagonist 7
  • HY-111079
    HIV-1 inhibitor-70
    Inhibitor
    HIV-1 inhibitor-70 (compound 20) is a bifunctional inhibitor that inhibits both wild-type (WT) and K103N mutant reverse transcriptases (RTs) of HIV-1.
    HIV-1 inhibitor-70
  • HY-125082
    SB 204144
    Inhibitor
    SB 204144 is an HIV protease inhibitor. SB 204144 can be used in research on immune system diseases.
    SB 204144
  • HY-14740S
    Elvitegravir-d8
    Inhibitor
    Elvitegravir-d8 is deuterium labeled Elvitegravir. Elvitegravir (GS-9137; JTK-303; D06677) is an HIV integrase inhibitor for HIV-1IIIB, HIV-2EHO and HIV-2ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM, respectively.
    Elvitegravir-d<sub>8</sub>
  • HY-N17346
    Neoaspidistrin
    Inhibitor
    Neoaspidistrin is a spirostanol saponin that can be found in the rhizomes of Aspidistra typica. Neoaspidistrin exhibits activity against HIV-1 by inhibiting viral replication. Neoaspidistrin can be used for the research of HIV-1 infection.
    Neoaspidistrin
  • HY-127135
    B07
    Inhibitor
    B07 is a HIV inhibitor. B07 also has spermicides activity (EC50: 1.5 mg/mL).
    B07
  • HY-14230
    INCB9471
    Inhibitor
    INCB9471 is a potent, selective and orally active CCR5 antagonist. INCB9471 shows anti-HIV-1 activity.
    INCB9471
  • HY-122229
    GS-9822
    Inhibitor
    GS-9822 is a potent antivira agent with nanomolar activity against wild-type HIV-1 viruses. GS-9822 potently inhibits the LEDGF/p75-integrase interaction with an IC50 of 0.07 μM. GS-9822 has high in vitro metabolic stability and favorable oral pharmacokinetic profiles with low systemic clearance in rats, dogs, and monkeys.
    GS-9822
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.